Chronic Myeloid Leukemia Coverage from Every Angle
Advertisement
Advertisement

Recent News

Can a Drug Approved for CML Affect Treatment of Degenerative Brain Diseases?
Update on Antitumor Activity of Natural Killer Cells in CML
Bone Marrow Molecule in Elimination of CML Stem Cells
TKI Initiation and Health-Care Costs for Patients With CML
Long-Term Patterns of Oral Anticancer Therapy Use in Patients With CML
ESMO 2019: Significance of BCR-ABL Transcript Variants in Chronic Phase CML
FDA Grants Clearance to Test for Monitoring Disease Burden in CML
SOHO 2019: Asciminib Plus Imatinib for Resistant CML
SOHO 2019: Update on Therapies for Advanced Phase Chronic Myeloid Leukemia
SOHO 2019: Case Study Explores Treatment Options After TKI Failure in CML
Targeting Epigenetic Processes in CML Cells
Can Imatinib Therapy Affect Growth of Children With CML?
Jerald Radich, MD, Named Inaugural Recipient of Kurt Enslein Endowed Chair at Fred Hutch
Case Report of CML With Primary Blast Crisis and Marrow Fibrosis
Infliximab Therapy With Tyrosine Kinase Inhibition in CML
Comparing Asciminib and Bosutinib in Resistant CML
Does SIRT1 Play a Role in Chronic Myeloid Leukemia Development?
Trial Update on Lower-Dose Dasatinib in Newly Diagnosed CML
Treatment-Free Remission After Dasatinib Discontinuation in CML
Long-Term Update on Treatment-Free Remission After First-Line Nilotinib in CML
EHA24 Congress: Phase IV BYOND Trial of Bosutinib in Resistant CML
EHA24 Congress: Cardiovascular Events and Nilotinib Treatment in CML
EHA24 Congress: Second-Generation TKI in CML After Suboptimal Response to Imatinib
ASCO 2019: BYOND Study Update on Bosutinib in Chronic Phase CML
ASCO 2019: Is Front-Line Flumatinib as Effective as Imatinib in CML?
ASCO 2019: Long-Term Follow-up on Treatment-Free Remission in CML
Use of Tyrosine Kinase Inhibitors During Pregnancy for Women With CML


By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.